Literature DB >> 32845486

One year experience with erenumab: real-life data in 30 consecutive patients.

Angelo Ranieri1,2, Gennaro Alfieri3,4, Massimo Napolitano3, Giovanna Servillo3, Paolo Candelaresi3, Walter Di Iorio3, Katia Longo3, Giorgia Teresa Maniscalco3, Rosaria Renna3, Mariana Rippa3, Simona Salvatore3, Anna Sagnelli3, Ciro Florio3, Valentino Manzo3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32845486     DOI： 10.1007/s10072-020-04677-y

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


× No keyword cloud information.
  9 in total

1.  Patient-reported outcomes of migraine treatment with erenumab: results from a national patient survey.

Authors:  Austėja Dapkutė; Jurgita Vainauskienė; Kristina Ryliškienė
Journal:  Neurol Sci       Date:  2022-01-10       Impact factor: 3.830

2.  Gender Differences in 3-Month Outcomes of Erenumab Treatment-Study on Efficacy and Safety of Treatment With Erenumab in Men.

Authors:  Raffaele Ornello; Carlo Baraldi; Simona Guerzoni; Giorgio Lambru; Matteo Fuccaro; Bianca Raffaelli; Astrid Gendolla; Piero Barbanti; Cinzia Aurilia; Sabina Cevoli; Valentina Favoni; Fabrizio Vernieri; Claudia Altamura; Antonio Russo; Marcello Silvestro; Elisabetta Dalla Valle; Andrea Mancioli; Angelo Ranieri; Gennaro Alfieri; Nina Latysheva; Elena Filatova; Jamie Talbot; Shuli Cheng; Dagny Holle; Armin Scheffler; Tomáš Nežádal; Dana Čtrnáctá; Jitka Šípková; Zuzana Matoušová; Lucia Sette; Alfonsina Casalena; Maurizio Maddestra; Stefano Viola; Giannapia Affaitati; Maria Adele Giamberardino; Francesca Pistoia; Uwe Reuter; Simona Sacco
Journal:  Front Neurol       Date:  2021-12-16       Impact factor: 4.003

3.  Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany.

Authors:  Andreas Straube; Philipp Stude; Charly Gaul; Katrin Schuh; Mirja Koch
Journal:  J Headache Pain       Date:  2021-11-06       Impact factor: 7.277

Review 4.  Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes.

Authors:  Eleonora De Matteis; Simona Sacco; Raffaele Ornello
Journal:  Ther Clin Risk Manag       Date:  2022-04-05       Impact factor: 2.423

5.  Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score.

Authors:  Luigi Francesco Iannone; Davide Fattori; Silvia Benemei; Alberto Chiarugi; Pierangelo Geppetti; Francesco De Cesaris
Journal:  CNS Drugs       Date:  2022-02-11       Impact factor: 5.749

6.  Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study.

Authors:  Raffaele Ornello; Carlo Baraldi; Simona Guerzoni; Giorgio Lambru; Anna P Andreou; Bianca Raffaelli; Astrid Gendolla; Piero Barbanti; Cinzia Aurilia; Gabriella Egeo; Sabina Cevoli; Valentina Favoni; Fabrizio Vernieri; Claudia Altamura; Antonio Russo; Marcello Silvestro; Elisabetta Dalla Valle; Andrea Mancioli; Angelo Ranieri; Gennaro Alfieri; Nina Latysheva; Elena Filatova; Jamie Talbot; Shuli Cheng; Dagny Holle; Armin Scheffler; Tomáš Nežádal; Dana Čtrnáctá; Jitka Šípková; Zuzana Matoušová; Alfonsina Casalena; Maurizio Maddestra; Stefano Viola; Giannapia Affaitati; Maria Adele Giamberardino; Francesca Pistoia; Uwe Reuter; Simona Sacco
Journal:  J Headache Pain       Date:  2022-03-19       Impact factor: 7.277

Review 7.  Reducing the Burden of Migraine: Safety and Efficacy of CGRP Pathway-Targeted Preventive Treatments.

Authors:  George R Nissan; Richard Kim; Joshua M Cohen; Michael J Seminerio; Lynda J Krasenbaum; Karen Carr; Vincent Martin
Journal:  J Clin Med       Date:  2022-07-27       Impact factor: 4.964

8.  Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real-world evidence.

Authors:  Modar Khalil; David Moreno-Ajona; María Dolores Villar-Martínez; Fiona Greenwood; Jan Hoffmann; Peter J Goadsby
Journal:  Eur J Neurol       Date:  2022-05-09       Impact factor: 6.288

9.  MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention.

Authors:  Robert Belvís; Pablo Irimia; Patricia Pozo-Rosich; Carmen González-Oria; Antonio Cano; Javier Viguera; Belén Sánchez; Francisco Molina; Isabel Beltrán; Agustín Oterino; Elisa Cuadrado; Angel Gómez-Camello; Miguel Alberte-Woodward; Carmen Jurado; Teresa Oms; David Ezpeleta; Javier Díaz de Terán; Noemí Morollón; Germán Latorre; Marta Torres-Ferrús; Alicia Alpuente; Raquel Lamas; Carlos Toledano; Rogelio Leira; Sonia Santos; Margarita Sánchez Del Río
Journal:  J Headache Pain       Date:  2021-07-17       Impact factor: 7.277
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.